Hugh Brent Solvason, MD PHD
Psychiatry · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 7
- 3 carriers
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plans that list them
7 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Solvason’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
7 of 7 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G81228 · Current
Licensed to practise in California · since 1995 · expires 2028-07-31 · University of Alabama School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$23,161
Pharmacies billed $23,161 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 127) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
106 generic and 21 brand-name prescriptions · $23,161 in drug cost · 17 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lurasidone | 11 | $3,275 | $298 |
| Gabapentin | 17 | $171 | $10 |
| Duloxetine | 13 | $137 | $11 |
Year by year
| 2024 | 127 | 12 | 0% (0) | 17% | $23,161 |
| 2023 | 90 | None | 0% (0) | None | $22,226 |
| 2022 | 85 | None | 0% (0) | 19% | $24,706 |
| 2021 | 52 | None | 0% (0) | None | $11,493 |
| 2020 | 125 | None | 0% (0) | None | $13,232 |
| 2019 | 157 | None | 0% (0) | 9% | $10,332 |
| 2018 | 73 | None | 0% (0) | 16% | $7,424 |
| 2017 | 44 | None | 0% (0) | None | $14,236 |
| 2016 | 25 | None | 0% (0) | None | $2,231 |
| 2015 | 75 | 14 | 0% (0) | 20% | $8,274 |
| 2014 | 203 | 12 | None | 37% | $36,844 |
| 2013 | 248 | 33 | 0% (0) | 23% | $60,574 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Lorazepam | 15 | $54 | $4 |
2022: 1 drug
| Latuda | 13 | $19,924 | $1,533 |
2021: 1 drug
| Oxcarbazepine | 12 | $297 | $25 |
2020: 4 drugs
| Oxcarbazepine | 18 | $1,088 | $60 |
| Quetiapine Fumarate Er | 24 | $1,025 | $43 |
| Memantine | 11 | $537 | $49 |
| Lithium Carbonate Er | 12 | $168 | $14 |
2019: 4 drugs
| Quetiapine Fumarate Er | 20 | $762 | $38 |
| Oxcarbazepine | 13 | $464 | $36 |
| Clonazepam | 25 | $366 | $15 |
| Lithium Carbonate | 18 | $169 | $9 |
2018: 2 drugs
| Bupropion Xl | 14 | $876 | $63 |
| Lithium Carbonate | 12 | $144 | $12 |
2017: 1 drug
| Lithium Carbonate | 13 | $164 | $13 |
2014: 5 drugs
| Fetzima | 23 | $9,414 | $409 |
| Nuvigil | 15 | $7,807 | $520 |
| Zaleplon | 20 | $277 | $14 |
| Lorazepam | 16 | $194 | $12 |
| Trazodone | 14 | $149 | $11 |
2013: 5 drugs
| Nuvigil | 13 | $9,239 | $711 |
| Quetiapine | 15 | $3,756 | $250 |
| Zaleplon | 12 | $250 | $21 |
| Lorazepam | 12 | $96 | $8 |
| Clonazepam | 13 | $77 | $6 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Neuronetics, Inc. · A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of Neurostar Transcranial Magnetic Stimulation (Tms) Therapy in Depressed Adolescents · 2019 | Their institution | $22,696 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1265577530
- Licence
- CA G81228California G81228: Current · expires 2028-07-31
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-21
- NPI last updated
- 2024-04-30
- NPI record certified
- 2024-04-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 401 Quarry Rd Rm 2138, Palo Alto, CA, 94304